Drugs / aspacytarabine
aspacytarabine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05503355 | Aug 2022 → Aug 2025 | acute myeloid leukemia | BioSight Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02544438 | Sep 2015 → Sep 2017 | acute lymphoblastic leukemia, acute myeloid leukemia | BioSight Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04749355 | Nov 2021 → Dec 2023 | acute myeloid leukemia, myelodysplastic syndrome | BioSight Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04827719 | May 2021 → Jan 2025 | acute myeloid leukemia, myelodysplastic syndrome | Groupe Francophone des Myelodysplasies | Completed | No outcome recorded |
| Phase 2 | NCT03435848 | Aug 2018 → Mar 2023 | acute myeloid leukemia | BioSight Ltd. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aspacytarabine | “Aspacytarabine, an inactive prodrug of cytarabine, was evaluated as monotherapy in a phase 2b study of patients unfit for intensive chemotherapy (NCT03435848).” PMID 37903324 ↗ Dec 2023 |
| Known as | Aspacitarabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297599 ↗ |
| Known as | ASPACYTARABINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297599 ↗ |
| Known as | Astarabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02544438 ↗ |
| Known as | BST-236 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04749355 ↗ |
| Known as | BST-236 HCl | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297599 ↗ |
| Modality | Small molecule | — CHEMBL4297599 ↗ |
| Route | Intravenous | “for IV administration” NCT04749355 ↗ |